Creative Biolabs: Setting a High Standard of Recombinant Antibody

Creative Biolabs announced in its latest release that they are determined to develop more recombinant antibodies of high affinity and versatility to facilitate global clients’ projects as best they can.

New York, USA – March 7, 2024 – In the February report meeting, Creative Biolabs pinned its resolution to supply recombinant antibodies of superior quality to global customers in favor of their endeavors into developing new drugs or disease studies.

“In the past 2023, we’ve witnessed breakthroughs, represented by those discoveries in the battle against COVID-19,” according to a scientist at Creative Biolabs, “and in most of the cases, antibodies play a core role. Realizing the significance of antibodies, we are determined to invest more, both our efforts and time, into this field.”

Creative Biolabs, proficient in life sciences like biomedical, immunology, and virology, has dedicated years to developing research-use antibodies and successfully established a high throughput antibody production system that produces and manufactures antibodies catering to miscellaneous requirements ranging from designated product scales to prevalent targets and dark horses.

“The system helps in a one-stop manner,” commented the scientist, “and that’s exactly how we are different from other CROs in the industry. The signal to kick-off is confirming the desired DNA sequence with our clients, and the endpoint is purified antibody delivery. The entire workflow will be customized according to their project requirements.”

Another crucial factor for Creative Biolabs to sustain such a steady and adequate supply is the cell-free recombinant antibody production platform, which has leaped beyond the traditional expression mechanisms to relieve animal usage and achieve free customization, easy manipulation, and productive translation.

Based upon those powerful platforms, Creative Biolabs is capable of sourcing high purity (over 98%), high affinity, and reproducible antibody reagents for research objectives like blocking antibodies, neutralizing antibodies, anti-idiotypic antibodies, and agonistic antibodies.

“We’ve been working in this area for over a decade and have gained extensive experience through all kinds of collaboration with clients from all over the world,” according to the scientist. “Even for the most specified or rare project target, we can find a way out.”

Creative Biolabs’ dedication to excellence and innovation has positioned the company as a leader in recombinant antibodies. By continuously refining their technologies and expanding their product offerings, Creative Biolabs remains a trusted partner for scientists seeking cutting-edge antibody solutions.

To learn more about Creative Biolabs and their innovative antibody products, visit:

Company Overview

Creative Biolabs is a leading provider of recombinant antibody reagents and related services, dedicated to advancing antibody-based therapies through innovation and excellence in antibody development. With a focus on quality and customer satisfaction, Creative Biolabs continues to drive advancements in the field of antibody research and therapeutic development.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States